Merck’s BELSOMRA C-IV meets primary efficacy endpoint in phase 3 trial

This article was originally published here

This is the first dedicated Phase 3 polysomnography study of an insomnia medication in people with mild-to-moderate Alzheimer’s disease dementia, and in the trial, BELSOMRA met its primary

The post Merck’s BELSOMRA C-IV meets primary efficacy endpoint in phase 3 trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply